PI3K/mTOR Inhibitor LY3023414

Known as: LY 3023414, LY-3023414, LY3023414 
An orally bioavailable, small molecule inhibitor of certain class I phosphoinositide 3-kinase (PI3K) isoforms and mammalian target of rapamycin… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2016-2018
012320162018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Biliary tract carcinoma (BTC) is an extremely malignant tumor, but available treatment options are limited. Despite of needs for… (More)
Is this relevant?
2017
2017
OBJECTIVE The purpose of the current study is to determine the efficacy of a PI3K/mTOR dual inhibitor, LY3023414, on established… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
Abnormal activation of PI3K-AKT-mTOR signaling is detected in human skin squamous cell carcinoma (SCC). LY3023414 is a novel… (More)
Is this relevant?
2017
2017
PI3K-AKT-mTOR signaling is a valuable treatment target for human glioma. LY3023414 is a novel, highly-potent and pan PI3K-AKT… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
The PI3K/AKT/mTOR pathway is among the most frequently altered pathways in cancer cell growth and survival. LY3023414 is a… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2016
2016
Therapeutic targeting of the PI3K pathway is an active area of research in multiple cancer types, including breast and… (More)
Is this relevant?
2016
2016
PURPOSE Effective systemic therapeutic options are limited for bladder cancer. In this preclinical study we tested whether… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?